<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04684667</url>
  </required_header>
  <id_info>
    <org_study_id>Essam Mowannas</org_study_id>
    <nct_id>NCT04684667</nct_id>
  </id_info>
  <brief_title>''Efficacy of Propranolol in the Treatment of Infantile Hemangioma&quot;</brief_title>
  <official_title>'' Efficacy of Propranolol in the Treatment of Infantile Hemangioma&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      ''Evaluation of the Efficacy of Propranolol in the Treatment of Infantile Hemangioma&quot;&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Infantile hemangiomas (IH) are benign tumors of vascular endothelium.They are the most common&#xD;
      tumors of infancy. They occur in about 4% of infants, though early studies were as high as&#xD;
      10%, probably due to the inclusion of other vascular lesions. The incidence is higher in&#xD;
      premature infants, Caucasians, and females (by a 3 to 5:1 ratio). Advanced maternal age,&#xD;
      multiple gestations, and placental abnormalities are also risk factors. IHs have a unique and&#xD;
      characteristic life cycle consisting of three phases: proliferative, involuting, and&#xD;
      involuted.&#xD;
&#xD;
      The majority of IHs do not require any specific treatment other than observation and&#xD;
      reassurance of the parents. Even tumors that exhibit rapid growth or fiery red skin will&#xD;
      spontaneously regress and leave behind little to no evidence of their presence. However,&#xD;
      regular follow-up is important as the potential complications have few clinical indicators.&#xD;
&#xD;
      Reasons for treatment include dangerous locations (impinging on a vital structure such as the&#xD;
      airway or eye), unusually large size or rapid growth, and local or endangering complications&#xD;
      (skin ulceration or high-output heart failure). Hemangiomas exhibiting the aforementioned&#xD;
      risk factors or complications should be considered for treatment. As hemangiomas are tumors&#xD;
      of pure angiogenesis, pharmacologic therapy involves angiogenesis inhibition.&#xD;
&#xD;
      Historically, steroids have been used as the primary treatment for IH. Steroids have been&#xD;
      shown to be antiangiogenic in a number of in vitro settings and also have shown good&#xD;
      therapeutic effects clinically. However, the use of steroids may lead to various&#xD;
      complications including gastroesophageal reflux and growth disorders, although these&#xD;
      complications are associated with long-term use and high dose. A type of anticancer drug or&#xD;
      immunomodulator, interferon alfa, may be used for severe IH in cases where patients did not&#xD;
      respond to steroids. However, interferon alfa also has several possible adverse effects,&#xD;
      including fever, muscle pain, systemic myalgia, and in severe cases, liver damage, blood&#xD;
      toxic effects, thyroid hormonal abnormality, and neurological and neurodevelopmental toxic&#xD;
      effects. Because of concerns about these adverse effects, many guardians of pediatric&#xD;
      patients prefer to wait rather than accept treatment.&#xD;
&#xD;
      Propranolol, a nonselective beta blocker, has recently been recognized as an important&#xD;
      treatment option for hemangiomas. In most centers, it has become first-line pharmacotherapy.&#xD;
      A child with a nasal capillary hemangioma treated with propranolol for steroid-induced&#xD;
      cardiomyopathy had regression of his lesion. This revelation led to the publication of&#xD;
      several more studies supporting this finding. Propranolol is given orally at 2-3 mg/kg/day,&#xD;
      in two or three divided doses, and discontinued following regression of the lesion. Treatment&#xD;
      often leads to a consistent, rapid, therapeutic effect with softening of the lesion on&#xD;
      palpation and color shift from intense red to purple. Propranolol is well tolerated but can&#xD;
      cause rare side effects such as bradycardia, gastroesophageal reflux, hypoglycemia,&#xD;
      hypotension, rash, somnolence, and wheezing.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This study will involve patients with infantile hemangiomas who will be admitted at the Assiut University Children Hospital between January 2021 and December 2021.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete clinical clearance of hemangioma or reduction of hemangioma's volume.</measure>
    <time_frame>within 9 months</time_frame>
    <description>The efficacy of the treatment will be evaluated by complete clinical clearance of lesion (defined arbitrarily as &gt;90% reduction in the size of Infantile Hemangioma as assessed by Physician Global Assessment) or after 9 months of treatment (primary end point) whichever is earlier for cutaneous infantile hemangiomas and by volume reduction of hemangiomas as evaluated by the proper imaging modalities ( Ultrasound, CT, or MRI) for non cutaneous hemangiomas.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Infantile Hemangioma</condition>
  <arm_group>
    <arm_group_label>Propranolol Therapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>This arm will involve patients with infantile hemangiomas who will be admitted at the Assiut University Children Hospital between January 2021 and December 2021.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol Therapy for Infantile Hemangioma</intervention_name>
    <description>If there are no contraindications to propranolol, it will be given at initial dose of 0.5 mg /kg/day in 2-3 divided doses with feeds and the patients will be observed for clinical signs of serious adverse reactions. If the dose is tolerated, it will be maintained for four to seven days, and then it will be increased by 0.5mg/kg/day every four days to the target dose of 2mg/kg/day. The patients will be observed for 2 hours after each dose increase for the clinical signs of severe side effects.</description>
    <arm_group_label>Propranolol Therapy</arm_group_label>
    <other_name>Propranolol Treatment for Infantile Hemangioma</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Children diagnosed with problematic infantile hemangiomas:&#xD;
&#xD;
        A-Large hemangiomas at increased risk of scarring or disfigurement at any site.&#xD;
        B-Hemangiomas carrying functional risks near the eyes, nose, natural orifices, limbs,&#xD;
        genitalia.&#xD;
&#xD;
        C-Ulcerated infantile hemangiomas. D-Uncomplicated progressive infantile hemangiomas with&#xD;
        unpredictable future course.&#xD;
&#xD;
        E-Life-threatening hemangiomas.&#xD;
&#xD;
          -  Multiple hemangiomas&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients older than 1 year of age.&#xD;
&#xD;
          -  Patients with heart diseases.&#xD;
&#xD;
          -  Patients with history of bronchspasm or wheezing.&#xD;
&#xD;
          -  Patients with Hypotension.&#xD;
&#xD;
          -  Patients with Hypertension.&#xD;
&#xD;
          -  Premature infants with corrected age less than 5 weeks.&#xD;
&#xD;
          -  Patients with conditions affecting blood glucose maintenance.&#xD;
&#xD;
          -  Patients with liver failure.&#xD;
&#xD;
          -  Patients with PHACES syndrome.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>1 Year</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Essam EA Mowannas, MD</last_name>
    <phone>+201285289188</phone>
    <email>essamezzat81@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Assiut University Teaching Hospital</name>
      <address>
        <city>Assiut</city>
        <zip>71526</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <contact>
      <last_name>Essam E.A Mowannas, MD</last_name>
      <phone>+201285289188</phone>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Darrow DH, Greene AK, Mancini AJ, Nopper AJ; SECTION ON DERMATOLOGY, SECTION ON OTOLARYNGOLOGY-HEAD AND NECK SURGERY, and SECTION ON PLASTIC SURGERY. Diagnosis and Management of Infantile Hemangioma. Pediatrics. 2015 Oct;136(4):e1060-104. doi: 10.1542/peds.2015-2485.</citation>
    <PMID>26416931</PMID>
  </reference>
  <reference>
    <citation>Darrow DH, Greene AK, Mancini AJ, Nopper AJ; SECTION ON DERMATOLOGY, SECTION ON OTOLARYNGOLOGY-HEAD &amp; NECK SURGERY, AND SECTION ON PLASTIC SURGERY. Diagnosis and Management of Infantile Hemangioma: Executive Summary. Pediatrics. 2015 Oct;136(4):786-91. doi: 10.1542/peds.2015-2482.</citation>
    <PMID>26416928</PMID>
  </reference>
  <reference>
    <citation>Léauté-Labrèze C, Harper JI, Hoeger PH. Infantile haemangioma. Lancet. 2017 Jul 1;390(10089):85-94. doi: 10.1016/S0140-6736(16)00645-0. Epub 2017 Jan 13. Review.</citation>
    <PMID>28089471</PMID>
  </reference>
  <reference>
    <citation>HOLMDAHL K. Cutaneous hemangiomas in premature and mature infants. Acta Paediatr. 1955 Jul;44(4):370-9.</citation>
    <PMID>13292246</PMID>
  </reference>
  <reference>
    <citation>Amir J, Metzker A, Krikler R, Reisner SH. Strawberry hemangioma in preterm infants. Pediatr Dermatol. 1986 Sep;3(4):331-2.</citation>
    <PMID>3774653</PMID>
  </reference>
  <reference>
    <citation>Hemangioma Investigator Group, Haggstrom AN, Drolet BA, Baselga E, Chamlin SL, Garzon MC, Horii KA, Lucky AW, Mancini AJ, Metry DW, Newell B, Nopper AJ, Frieden IJ. Prospective study of infantile hemangiomas: demographic, prenatal, and perinatal characteristics. J Pediatr. 2007 Mar;150(3):291-4.</citation>
    <PMID>17307549</PMID>
  </reference>
  <reference>
    <citation>Margileth AM, Museles M. Cutaneous hemangiomas in children. Diagnosis and conservative management. JAMA. 1965 Nov 1;194(5):523-6.</citation>
    <PMID>5897362</PMID>
  </reference>
  <reference>
    <citation>Bennett ML, Fleischer AB Jr, Chamlin SL, Frieden IJ. Oral corticosteroid use is effective for cutaneous hemangiomas: an evidence-based evaluation. Arch Dermatol. 2001 Sep;137(9):1208-13.</citation>
    <PMID>11559219</PMID>
  </reference>
  <reference>
    <citation>Greenberger S, Boscolo E, Adini I, Mulliken JB, Bischoff J. Corticosteroid suppression of VEGF-A in infantile hemangioma-derived stem cells. N Engl J Med. 2010 Mar 18;362(11):1005-13. doi: 10.1056/NEJMoa0903036.</citation>
    <PMID>20237346</PMID>
  </reference>
  <reference>
    <citation>Crum R, Szabo S, Folkman J. A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. Science. 1985 Dec 20;230(4732):1375-8.</citation>
    <PMID>2416056</PMID>
  </reference>
  <reference>
    <citation>Boon LM, MacDonald DM, Mulliken JB. Complications of systemic corticosteroid therapy for problematic hemangioma. Plast Reconstr Surg. 1999 Nov;104(6):1616-23.</citation>
    <PMID>10541160</PMID>
  </reference>
  <reference>
    <citation>Barlow CF, Priebe CJ, Mulliken JB, Barnes PD, Mac Donald D, Folkman J, Ezekowitz RA. Spastic diplegia as a complication of interferon Alfa-2a treatment of hemangiomas of infancy. J Pediatr. 1998 Mar;132(3 Pt 1):527-30.</citation>
    <PMID>9544915</PMID>
  </reference>
  <reference>
    <citation>Deb G, Jenkner A, Donfrancesco A. Spastic diplegia and interferon. J Pediatr. 1999 Mar;134(3):382.</citation>
    <PMID>10064684</PMID>
  </reference>
  <reference>
    <citation>Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taïeb A. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008 Jun 12;358(24):2649-51. doi: 10.1056/NEJMc0708819.</citation>
    <PMID>18550886</PMID>
  </reference>
  <reference>
    <citation>Sans V, de la Roque ED, Berge J, Grenier N, Boralevi F, Mazereeuw-Hautier J, Lipsker D, Dupuis E, Ezzedine K, Vergnes P, Taïeb A, Léauté-Labrèze C. Propranolol for severe infantile hemangiomas: follow-up report. Pediatrics. 2009 Sep;124(3):e423-31. doi: 10.1542/peds.2008-3458. Epub 2009 Aug 10.</citation>
    <PMID>19706583</PMID>
  </reference>
  <reference>
    <citation>Buckmiller LM, Munson PD, Dyamenahalli U, Dai Y, Richter GT. Propranolol for infantile hemangiomas: early experience at a tertiary vascular anomalies center. Laryngoscope. 2010 Apr;120(4):676-81. doi: 10.1002/lary.20807.</citation>
    <PMID>20112413</PMID>
  </reference>
  <reference>
    <citation>Bagazgoitia L, Torrelo A, Gutiérrez JC, Hernández-Martín A, Luna P, Gutiérrez M, Baño A, Tamariz A, Larralde M, Alvarez R, Pardo N, Baselga E. Propranolol for infantile hemangiomas. Pediatr Dermatol. 2011 Mar-Apr;28(2):108-14. doi: 10.1111/j.1525-1470.2011.01345.x. Epub 2011 Mar 8.</citation>
    <PMID>21385205</PMID>
  </reference>
  <reference>
    <citation>Cushing SL, Boucek RJ, Manning SC, Sidbury R, Perkins JA. Initial experience with a multidisciplinary strategy for initiation of propranolol therapy for infantile hemangiomas. Otolaryngol Head Neck Surg. 2011 Jan;144(1):78-84. doi: 10.1177/0194599810390445.</citation>
    <PMID>21493392</PMID>
  </reference>
  <reference>
    <citation>Holland KE, Frieden IJ, Frommelt PC, Mancini AJ, Wyatt D, Drolet BA. Hypoglycemia in children taking propranolol for the treatment of infantile hemangioma. Arch Dermatol. 2010 Jul;146(7):775-8. doi: 10.1001/archdermatol.2010.158.</citation>
    <PMID>20644039</PMID>
  </reference>
  <reference>
    <citation>Harrison DC, Meffin PJ, Winkle RA. Clinical pharmacokinetics of antiarrhythmic drugs. Prog Cardiovasc Dis. 1977 Nov-Dec;20(3):217-42. Review.</citation>
    <PMID>335439</PMID>
  </reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>April 29, 2020</study_first_submitted>
  <study_first_submitted_qc>December 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2020</study_first_posted>
  <last_update_submitted>December 23, 2020</last_update_submitted>
  <last_update_submitted_qc>December 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Essam Ezzat Anees Mowannas</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Hemangioma</keyword>
  <keyword>Propranolol</keyword>
  <keyword>Beta Blockers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemangioma</mesh_term>
    <mesh_term>Hemangioma, Capillary</mesh_term>
    <mesh_term>Port-Wine Stain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>all collected IPD.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>The data is anticipated to become available on or after August 2022 and it will remain available for 5 years.</ipd_time_frame>
    <ipd_access_criteria>will be provided later</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

